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Background. Identification of new therapeutic targets remains an imperative goal to improve the morbidity
and mortality associated with severe sepsis and septic shock. Macrophage migration inhibitory factor (MIF), a
proinflammatory cytokine and counterregulator of glucocorticoids, has recently emerged as a critical mediator of
innate immunity and experimental sepsis, and it is an attractive new target for the treatment of sepsis.
Methods. Circulating concentrations of MIF were measured in 2 clinical trial cohorts of 145 pediatric and
adult patients who had severe sepsis or septic shock caused predominantly by infection with Neisseria meningitidis
or other gram-negative bacteria, to study the kinetics of MIF during sepsis, to analyze the interplay between MIF
and other mediators of sepsis or stress hormones (adrenocorticotropic hormone and cortisol), and to determine
whether MIF is associated with patient outcome.
Results. Circulating concentrations of MIF were markedly elevated in 96% of children and adults who had
severe sepsis or septic shock, and they remained elevated for several days. MIF levels were correlated with sepsis
severity scores, presence of shock, disseminated intravascular coagulation, urine output, blood pH, and lactate and
cytokine levels. High levels of MIF were associated with a rapidly fatal outcome. Moreover, in meningococcal
sepsis, concentrations of MIF were positively correlated with adrenocorticotropic hormone levels and negatively
correlated with cortisol levels and the cortisol:adrenocorticotropic hormone ratio, suggesting an inappropriate
adrenal response to sepsis.
Conclusions. MIF is markedly and persistently up-regulated in children and adults with gram-negative sepsis
and is associated with parameters of disease severity, with dysregulated pituitary-adrenal function in meningococcal
sepsis, and with early death.
Numerous adjunctive therapies for patients with severe
sepsis and septic shock have been tested in clinical trials.
Until recently, most antisepsis therapies yielded dis-
appointing results. However, the use of drotrecogin alfa
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(activated), corticosteroid therapy, and early goal–di-
rected therapy has recently given encouraging results
in adult patients [1–3]. However, identification of new
therapeutic targets to further improve the morbidity
and mortality associated with severe sepsis and septic
shock remains an imperative goal.
Discovered 40 years ago as a T cell cytokine that
inhibited macrophage motility [4, 5], macrophage mi-
gration inhibitory factor (MIF) remained an enigmatic
molecule until its rediscovery in the early 1990s as a
neuroendocrine peptide and an effector molecule of
innate immunity [6]. Constitutively expressed by en-
docrine and immune cells, MIF is released in a hor-
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mone-like fashion by the anterior pituitary gland and the ad-
renal cortex after exposure to endotoxin (lipopolysaccharide
[LPS]), corticotropin-releasing hormone, or physiological stress
[6–9]. MIF is also released by innate immune cells that are
exposed to proinflammatory mediators and microbial products,
and it acts to promote inflammatory and immune responses
[10, 11].
Interestingly, MIF and corticosteroids together function as a
homeostatic counterregulatory dyad modulating inflammatory
and immune responses [7]. Low doses of corticosteroids were
found to induce MIF release, which, in turn, counterbalanced
the immunosuppressive and antiinflammatory effects of glu-
cocorticoids. Cytoplasmic phospholipase A2 and mitogen-ac-
tivated protein kinase phosphatase 1 have been identified as
key molecular targets of MIF-glucocorticoid crosstalk [12, 13].
The expression of Toll-like receptor 4, the signal transducing
molecule of the LPS receptor complex, is up-regulated by MIF,
thereby facilitating the detection of gram-negative bacteria [14].
Moreover, MIF has been shown to play an important role in
experimental sepsis [6, 7, 11, 15, 16], acute respiratory distress
syndrome, and several inflammatory and autoimmune diseases
(reviewed in [17]). Thus, many lines of evidence indicate that
MIF is an interesting candidate target for therapeutic inter-
vention in patients who have severe sepsis.
In the present study, we measured circulating concentrations
of MIF in 2 clinical trial cohorts of patients with severe sepsis
or septic shock comprising children with meningococcal sepsis
and adults with gram-negative sepsis. We studied the kinetics
of MIF release in the systemic circulation during sepsis; the
interplay between MIF, mediators of sepsis, and stress hor-
mones (adrenocorticotropic hormone [ACTH] and cortisol);
and whether MIF was associated with patient outcome, and if
so, whether it might help to identify patients who may benefit
from anti-MIF treatment strategies.
METHODS
Adult patients. The adult study population consisted of 68
patients with sepsis, severe sepsis, or septic shock who were
part of a prospective, double-blind study that investigated the
efficacy of 2 IgG preparations for the treatment of gram-neg-
ative severe sepsis and septic shock [18]. Severe sepsis and septic
shock were defined as previously reported [18, 19]. Clinical and
laboratory parameters were recorded at study entry (i.e., near
the onset of severe sepsis or septic shock) and during the course
of disease. The evaluation of patient outcome was made pro-
spectively at the time of the study [18, 19]. Patients were clas-
sified as having survived (“survivors”); as having died of ful-
minant, irreversible septic shock (“early death”); or as having
died of an indirect consequence or of a relapse of shock after
transient reversal of shock, defined as a normalization of blood
pressure and discontinuation of supportive vasopressor therapy
(“late death”). The severity of underlying diseases was reported
according to the classification proposed by McCabe and Jackson
[20]. Concentrations of MIF were also measured in 196 healthy
subjects. The study was approved by the ethics committees of
the participating centers, and informed consent was obtained
from patients or from their relatives [19].
Pediatric patients. The pediatric study population con-
sisted of 77 patients who were admitted to the pediatric in-
tensive care unit of the Erasmus MC–Sophia (Rotterdam, The
Netherlands) who had been enrolled in meningococcal sepsis
studies [21–25]. All studies were approved by the ethical com-
mittee of the Erasmus Medical Center, and informed consent
was obtained from the parents or guardians of patients. In-
clusion criteria (tachycardia, tachypnea, rectal body temper-
ature !36C or 138.5C, and petechiae) were in accordance
with the recommendations of the International Pediatric Sep-
sis Consensus Conference [26]. Clinical data, severity scores,
and laboratory parameters were collected at study entry and
during the course of disease, as has been previously defined
[27, 28]. Neisseria meningitidis serogroups were determined
at The Netherlands Reference Laboratory for Bacterial Men-
ingitis (Academic Medical Center Amsterdam, Amsterdam,
The Netherlands).
Blood sampling and cytokine, coagulation factor, and stress
hormone measurements. In adult patients, serum samples
were collected at study entry (i.e., before the infusion of im-
munoglobulins), 2 h thereafter (for 61 patients), at day 1 (for
57 patients), and at day 10 (for 41 patients). In children, citrate
plasma samples were obtained at baseline (i.e., within 4 h of
pediatric intensive care unit admission for 71 patients and at
later time-points for 6 patients) and 12 h (for 23 patients) and
24 h (for 62 patients) thereafter. Convalescent blood samples,
obtained 3 months after hospital admission, was obtained from
13 patients. Serum and plasma samples were stored at 80C
and underwent, at most, 2 freeze and thaw cycles before being
assayed blindly. Concentrations of MIF were measured using
ELISA, as described elsewhere [29]. The analytic sensitivity of
the human MIF ELISA was 39 pg/mL. Intrarun and interrun
coefficients of variation were 6% and 12%, respectively. Con-
centrations of cholesterol, ACTH, cortisol, C-reactive protein,
procalcitonin TNF, IL-1b, IL-1ra, IL-6, IL-8, IL-10, macrophage
inflammatory protein–1b, activated protein C, thrombin-an-
tithrombin III complexes, and plasminogen activator inhibitor–
1 were determined as previously described [19, 22–25, 30, 31].
Statistical analysis. Comparison among groups was as-
sessed using the Kruskall-Wallis test for continuous variables
and Pearson’s x2 or Fisher’s exact test for categorical variables,
as appropriate. Spearman’s correlation coefficient was used to
evaluate the correlation between concentrations of MIF and
other laboratory parameters. The interday differences for cy-
tokine levels were evaluated using the Wilcoxon signed-rank
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Table 1. Characteristics of adult patients in the study population, by outcome.
Characteristic
Survivors
(n p 36)
Early death group
(n p 20)
Late death group
(n p 12)
Age, years 52 (7–78) 58.5 (21–74) 67 (34–76)
Male sex, no. (%) of patients 18 (50) 17 (85) 9 (75)
Severity of underlying diseases, no. of patients
Rapidly fatal 0 2 3
Ultimately fatal 7 5 5
Nonfatal 29 13 4
Corticosteroid use, no. (%) of patients
None 27 (75) 13 (65) 6 (50)
Chronic use 2 (6) 4 (20) 1 (8)
Acute use 7 (19) 3 (15) 5 (42)
Site of infection, no. of patients
Intraabdominal 11 9 6
Respiratory tract 9 6 2
Genitourinary tract 6 2 0
Skin and soft-tissue 1 2 1
CNS 3 1 0
Other site 0 0 1
No site identified 6 0 2
Pathogen, no. of patientsa
Gram-negative bacteria 19 13 5
Gram-positive bacteria 3 0 1
Fungi 3 0 0
Mixed infections 6 7 5
Not documented 5 0 1
Temperature, C 38.2 (35.0–40.4) 37.3 (35.6–40.4) 38.1 (35.9–39.4)
Mean arterial pressure, mm Hg 63 (17–115) 60 (23–87) 62.5 (47–85)
Duration of hypotension, h 12 (2–36) 11.5 (0–96) 10 (3–144)
Urine output, mL/min 30 (0–200) 0 (0–170) 27.5 (0–60)
Arterial pH 7.39 (7.27–7.57) 7.30 (7.17–7.47) 7.38 (7.26–7.52)
Leukocyte count, G/L 10.25 (0.2–42.0) 6.2 (0.1–100) 6.95 (0.8–13.7)
Thrombocyte count, G/L 89.5 (17–516) 73 (22–352) 109 (12–400)
NOTE. Data are median (range), unless otherwise indicated. Adult patients were classified as having survived (survivors);
as having died of fulminant, irreversible septic shock (early death group); or as having died of an indirect consequence or of a
relapse of shock after transient reversal of shock, defined as a normalization of blood pressure and discontinuation of supportive
vasopressor therapy (late death group). The 3 groups of patients differed in sex ratio ( ), severity of the underlying diseasePp .02
( ), age ( ), urine output ( ), arterial pH ( ), and time to death ( ).Pp .01 Pp .09 P ! .001 Pp .02 P ! .001
a Some patients had mixed infections.
test. The risk of death associated with blood MIF levels was
assessed using logistic regression analyses. Two-sided P values
!.05 were considered to indicate statistical significance. Anal-
yses were performed using SPSS software, version 14.0 (SPSS)
and STATA software, version 9.0 (Statacorp).
RESULTS
Adult patients. Among the 68 adult patients, 15 (22%) pre-
sented with severe sepsis and 53 (78%) presented with septic
shock. Thirty-two patients (47%) died. Nonsurvivors had been
prospectively subdivided into 2 groups: 20 patients (29%) who
rapidly died of fulminant, irreversible septic shock (early death;
median time to death, 2.5 days) and 12 patients (18%) who
experienced late death (median time to death, 14.5 days). Table
1 lists the demographic, clinical, and laboratory characteristics
of the survivor group, the early death group, and the late death
group. Sepsis was caused by gram-negative bacteria in 54 pa-
tients (80%), by gram-positive bacteria in 4 patients (6%), and
by Candida albicans in 3 patients (4%). In 7 patients (10%),
all sample cultures had negative results. Blood cultures had
positive results in 43 patients (63%) (table 2). Polymicrobial
bacteremia occurred in 8 patients (12%).
MIF was detected in the serum samples of all patients who
were enrolled in the study. MIF levels were much higher among
patients with sepsis (median level at study entry, 103.7 ng/mL;
range, 1.4–3200 ng/mL) than among healthy subjects (median
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Table 2. Microorganisms isolated from blood samples obtained
from adult study patients.
Microorganism No. of isolates
Gram-negative bacteria
Escherichia coli 14
Pseudomonas species 7
Klebsiella species 4
Enterobacter species 3
Neisseria meningitidis 3
Serratia species 2
Citrobacter species 1
Proteus species 1
Bacteroides species 1
Other 2
Gram-positive bacteria
Staphylococcus aureus 1
Enterococcus faecalis 1
Coagulase-negative staphylococci 1
Fungi
Candida albicans 2
Table 3. Characteristics of pediatric patients with meningococcal sepsis, by outcome.
Characteristic
Survivors
(n p 67)
Nonsurvivors
(n p 10)
Age, median years (range) 4.38 (0.12–16.11) 1.10 (0.46–9.43)
Male sex 41 (61) 8 (80)
Shock 61 (92) 10 (100)
Receipt of mechanical ventilation 41 (62) 10 (100)
Disseminated intravascular coagulation 34 (51) 10 (100)
PRISM score within first 6 h, median score (range) 20.0 (4–37) 31.5 (23–43)
Predicted mortality based on the Rotterdam score, % (range) 5.9 (0.0–96.3) 95.9 (55.1–99.6)
Documentation of Neisseria meningitidis infection
Blood culture 55 (82) 10 (100)
PCR 2 (3) 0
Neisseria meningitidis serogroup
B 39 (75) 7 (87.5)
C 13 (25) 1 (12.5)
NOTE. Data are no. (%) of patients, unless otherwise indicated. The 2 groups of patients differed in age (Pp
), need for mechanical ventilation ( ), presence of disseminated intravascular coagulation ( ), PRISM.002 Pp .03 Pp .004
score ( ), and predicted mortality ( ). PRISM, pediatric risk of mortality.Pp .001 P ! .001
level at study entry, 5.2 ng/mL; range, 2.8–15.5 ng/mL; P !
). Serum concentrations of MIF continued to increase.001
within 2 h after study entry (median, 131.5 ng/mL; range, 2.5–
3200 ng/mL) and progressively decreased thereafter (median
level at day 1, 73.7 ng/mL; range, 5.2–1772 ng/mL; median
[range] at day 10, 50.3 ng/mL; range, 0–388 ng/mL). In 71%
of the patients, peak levels of MIF were reached within 2 h
after enrollment. Only 3 patients (4%) had peak MIF levels
(1.4, 5.9, and 6.5 ng/mL) that were within the range for healthy
subjects, probably because of chemotherapy-induced neutro-
penia (defined as an absolute neutrophil count !100 cells/mm3)
in 1 patient and because of treatment with high doses of hy-
drocortisone or methylprednisolone in the other 2 patients.
Twenty-two patients (32%) were receiving corticosteroid ther-
apy at study entry, which had a significant impact on the cir-
culating MIF levels that were measured at study entry (Pp
). Interestingly, patients who had been receiving long-term.001
prednisone therapy ( ) had higher MIF levels (mediannp 7
level, 350.3 ng/mL; range, 52.5–525 ng/mL) than those who
had not received corticosteroids (median level, 109.1 ng/mL;
range, 4.2–1585.5 ng/mL; ), whereas patients who werePp .07
treated shortly before enrollment with high doses of hydro-
cortisone, methyprednisolone, or dexamethasone ( ) fornp 15
the treatment of sepsis had much lower MIF levels (median
level, 37.7 ng/mL; range, 1.4–3200 ng/mL; ).Pp .003
Peak MIF serum concentrations (defined as the highest MIF
level within the first 2 h after study entry) were inversely cor-
related with urine output ( ; ) and, to a lesserRp.37 Pp .002
extent, with arterial pH ( ; ). There was a trendRp.22 Pp .07
toward a positive correlation between MIF levels and leukocyte
counts ( ; ), a finding that was in agreementRp .21 Pp .09
with the observation of low MIF levels in a neutropenic patient.
Serum concentrations of MIF were found to correlate with
those of macrophage inflammatory protein–1b ( ), IL-Pp .001
1b ( ) and, to a lesser extent, with those of plasminogenPp .05
activator inhibitor–1 ( ), IL-8 ( ), and IL-6Pp .06 Pp .09
( ), but not with those of TNF ( )Pp .10 Pp .25
Pediatric patients with meningococcal sepsis. The de-
mographic, clinical, and microbiological characteristics of the
77 pediatric patients are shown in table 3. Seventy-one patients
(92%) presented with septic shock and 6 (8%) presented with
with severe sepsis, and 10 patients (13%) died. N. meningitidis
was isolated from blood samples by culture in 65 patients and
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Figure 1. Correlations between levels of macrophage migration inhib-
itory factor (MIF) and adrenocorticotropic hormone (ACTH; A), MIF and
cortisol levels (B), and MIF level and the cortisol:ACTH ratio (C), measured
at admission to the hospital, in children with meningococcal severe sepsis
and septic shock. Black circles, nonsurvivors; gray circles, survivors. Spear-
man’s correlation coefficients: (A), (B), andRp .597 Rp.355 Rp
(C)..627
Figure 2. Box plots of macrophage migration inhibitory factor (MIF)
levels in adults (A) and in children (B). The bottom, median, and top lines
of the box mark the 25th, 50th, and 75th percentiles, respectively. The
vertical line with whiskers shows the range of values. A, Survivors and
nonsurvivors subdivided into those who experienced late death and those
who experienced early death. Global P value, ; those who ex-P ! .001
perienced early death versus survivors, ; and those who ex-Pp .001
perienced early death versus those who experienced late death, P !
; survivors versus those who experienced late death, . B,.001 Pp .23
survivors and nonsurvivors, .P ! .001
by PCR in 2. The other 10 patients had possible meningococcal
infections on the basis of clinical criteria [27]. At study entry,
concentrations of MIF were found to be negatively correlated
with patient age ( ) and positively correlated with pe-P ! .001
diatric risk of mortality score ( ) and predicted mortalityP ! .001
( ) on the basis of Rotterdam score. MIF levels wereP ! .001
also significantly higher in patients who had disseminated in-
travascular coagulation (median level, 74 ng/mL; range, 22–
560 ng/mL) than in those who did not (median level, 36 ng/
mL; range, 8–235 ng/mL; ) and higher in patients withP ! .001
shock (median level, 57 ng/mL; range, 18–560 ng/mL) than in
those who did not experience shock (median level, 20 ng/mL;
range, 2–35 ng/mL; ). Moreover, MIF levels were pos-P ! .001
itively correlated with lactate and procalcitonin levels (Pp
and , respectively), whereas they were negatively.006 Pp .016
correlated with levels of C-reactive protein ( ) and cho-Pp .02
lesterol ( ). Serum concentrations of MIF were posi-Pp .001
tively correlated with levels of IL-1b ( ), IL-1ra (P ! .001 Pp
), IL-6 ( ), IL-8 ( ), and soluble TNF re-.002 Pp .001 Pp .001
ceptor ( ) and, to a lesser extent, with levels of TNFPp .01
( ) and IL-10 ( ). In addition, MIF was correlatedPp .08 Pp .08
with thrombin-antithrombin III complexes ( ), plas-Pp .003
minogen activator inhibitor–1 ( ), and activated pro-Pp .006
tein C ( ).Pp .02
MIF and the hypothalamo-pituitary-adrenal (HPA)
function. The relationship between circulating levels of MIF
and stress hormones (ACTH and cortisol) was examined in
children with meningococcal sepsis. Interestingly, circulating
concentrations of MIF were found to be positively correlated
with ACTH levels ( ) (figure 1A) and negatively cor-P ! .001
related with cortisol levels ( ) (figure 1B) and with thePp .005
cortisol:ACTH ratio ( ) (figure 1C). Although ACTHP ! .001
stimulation tests were not performed, the stress hormone pro-
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Table 4. Kinetics of blood macrophage migration inhibitory factor (MIF) concentrations
in adult and pediatric study patients, by outcome.
MIF concentration Survivors Nonsurvivors Early death group Late death group
Adult patients
At study entry 71 (4–717) … 165 (124–369) 51 (14–350)
After 2 h 75 (3–1131) … 447 (92–743) 106 (27–299)
On day 1 108 (5–862) … 670 (110–1772) 87 (23–317)
On day 10 36 (0–273) … 231 (118–388) 55 (4–191)
Pediatric patients
At study entry 53 (2–235) 161 (56–561) … …
After 12 h 43 (18–155) 207 (202–735) … …
After 24 h 32 (2–386) 347 (213–481) … …
NOTE. Values are median (range). Adult patients were classified as having survived (survivors); as having
died of fulminant, irreversible septic shock (early death group); or as having died of an indirect consequence
or of a relapse of shock after transient reversal of shock, defined as a normalization of blood pressure and
discontinuation of supportive vasopressor therapy (late death group). Pediatric patients were classified as
having survived (survivors) or as having died (nonsurvivors).
file showing an inverse correlation between ACTH and cortisol
levels ( ) was very suggestive of an inappropriate adrenalP ! .001
response to ACTH. This was particularly obvious in nonsur-
vivors in whom blood profiles exhibited a typical pattern of
high MIF levels and a low cortisol:ACTH ratio pathognomonic
of a dysregulated MIF-glucocorticoid balance with an exuberant
proinflammatory response (figure 1C).
MIF and survival. Peak serum levels of MIF differed mark-
edly between the 3 groups of adult patients ( ) (figureP ! .001
2A). Levels were markedly higher in the 20 patients in the early
death group (median level, 425.9 ng/mL; range, 73.6– 3200 ng/
mL)) than in the 36 survivors (median level, 108.2 ng/mL;
range, 5.9–1236.8 ng/mL; ) or in the 12 patients inPp .001
the late death group (median level, 78.0 ng/mL; range, 2.5–
350.3 ng/mL; ) ( for survivors vs. late deathP ! .001 Pp .23
group). At study entry, each incremental elevation of 100 ng/
mL of MIF increased the risk of early death by a factor of 1.67
(95% CI, 1.17–2.41; ). This finding remained signif-Pp .005
icant (OR, 1.49; 95 % CI, 1.02–2.19; ) after adjustmentsPp .03
for sex and urine output, 2 variables that were significantly
associated with MIF levels and the risk of death. Table 4 shows
the kinetics of MIF levels in survivors and nonsurvivors over
a 10-day period.
Circulating concentrations of MIF were also associated with
outcome in children with meningococcal sepsis. MIF levels were
significantly higher in nonsurvivors than in survivors (at study
entry, ; at 12 h, ; and at 24 h, ) (figureP ! .001 Pp .005 Pp .01
2B and table 4). Similar to the observation made in adults,
each incremental elevation of 100 ng/mL of MIF increased the
risk of death by a factor of 7.4 (95% CI, 2.1–26; ).Pp .002
Levels of MIF measured in convalescent children 3 months after
admission were significantly lower than those measured at ad-
mission ( ).Pp .009
DISCUSSION
Analyses of the kinetics of blood MIF in 2 cohorts of 145
patients with gram-negative severe sepsis and septic shock
caused by N. meningitidis infection in children and predomi-
nantly caused by Enterobacteriaceae and Pseudomonas species
infection in adults revealed that 96% of the pediatric and adult
patients with severe sepsis or septic shock had elevated MIF
levels that were 10 times above the normal range of MIF con-
centrations in healthy subjects. These results confirm and ex-
tend previous findings of 4 series of patients who had either
systemic inflammatory response syndrome, severe sepsis, or
septic shock [32–35]. MIF levels remained elevated for at least
10 days after the onset of severe sepsis and septic shock. This
rather unique kinetic profile offers a wide window for thera-
peutic interventions that is likely to be a major advantage for
the design of future clinical trials with anti-MIF therapies that
are currently under development.
MIF levels were correlated with sepsis severity scores (pe-
diatric risk of mortality score and predicted mortality rates in
children with meningococcal sepsis), morbidity (presence of
shock, disseminated intravascular coagulation, low urine out-
put and arterial pH, and high lactate levels), and, importantly,
with mortality. Indeed, very high MIF levels at the onset of
sepsis were associated with fulminant and rapidly fatal disease.
In contrast, adults in the late death group of patients who
initially recovered from shock but who died later from com-
plications of shock or from a relapse of sepsis had MIF levels
that were in the range of those of survivors. Therefore, mea-
surement of blood MIF may help to identify patients with poor
prognosis and in whom anti-MIF treatment strategies might
improve survival.
Consistent with its proinflammatory activities, MIF level was
found to be correlated with markers of inflammation or sepsis
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(C-reactive protein and procalcitonin levels in children) and
with proinflammatory cytokine levels. However, some discrep-
ancies were observed between children and adults with respect
to correlations between MIF and proinflammatory cytokine
(TNF, IL-6, and IL-8) levels. Several factors may account for
these discrepancies, such as the timing of blood sampling; the
patient’s age, which might influence MIF responses (a hypoth-
esis that deserves further investigation); the type of infections
(community-acquired infections in children vs. a mixture of
community-acquired and health care–related infections in
adults); the underlying risk factors (e.g., meningococcal sepsis
typically occurs in young, otherwise healthy subjects with low
bactericidal antibody titers, whereas gram-negative sepsis in
adults occurs in the context of comorbidities likely to affect
the magnitude of cytokine responses); and, of course, the eti-
ology of sepsis (N. meningitidis infection in children vs. En-
terobacteriaceae and Pseudomonas species infection in adults).
Indeed, in contrast to other types of gram-negative sepsis, me-
ningococcal sepsis usually follows a fulminant course charac-
terized by a rapid invasion of the bloodstream, very high con-
centrations of endotoxin in the systemic circulation, and the
induction of a vigorous cytokine response and powerful acti-
vation of the complement and coagulation systems [36]. Con-
sistent with these observations and with previous findings of
an association between increased plasminogen activator inhib-
itor–1 levels and increased mortality associated with menin-
gococcal sepsis or gram-negative septic shock, as well as with
findings regarding the impact of activated protein C on LPS-
induced MIF release [30, 37], MIF levels were positively cor-
related with disseminated intravascular coagulation and with
levels of plasminogen activator inhibitor–1, thrombin-antith-
rombin III complexes, and activated protein C.
Activation of the HPA axis is an essential feature of the
systemic stress response to infection, resulting in the release of
glucocorticoids, which play an essential role in the regulation
of the host inflammatory and immune responses [38]. One of
the intriguing features of MIF has been its abundant expression
in the pituitary and adrenal glands and its circulation in the
bloodstream with a circadian rhythm synchronous with that of
glucocorticoids [6, 8, 9, 39]. Moreover, low doses of gluco-
corticoids have previously been shown to induce MIF release,
whereas high doses were found to suppress MIF expression [7,
40, 41]. In turn, MIF overrides the immunosuppressive and
antiinflammatory effects of glucocorticoids [7], leading to the
concept that MIF and glucocorticoids function as a physiolog-
ical counterregulatory dyad that modulates inflammatory and
immune responses. In line with these observations, treatment
with long-term corticosteroids was associated with a 3.5-fold
up-regulation of MIF levels at study entry, whereas treatment
with short-term high-dose corticosteroids caused a 3.0-fold
down-regulation of MIF levels. The positive correlation noted
between MIF and ACTH levels measured at admission in chil-
dren with meningococcal septic shock are well in agreement
with the fact that corticotropin-releasing hormone and LPS are
powerful MIF secretagogues in the pituitary gland [8]. In con-
trast to what is observed in adults with sepsis [35], MIF levels
were inversely correlated with cortisol levels in septic children
and, thus, with the cortisol:ACTH ratio, which is consistent
with previous observations that high doses of corticosteroids
inhibit MIF production [7, 40, 41]. Cholesterol, the starting
compound of cortisol synthesis, is a major lipid constituent of
high-density lipoproteins, which are very potent inhibitors of
LPS activity in vivo and a prognostic factor of susceptibility to
and outcome of sepsis [24, 42]. When forming complexes with
high-density lipoproteins and LPS, cholesterol may no longer
be used for cortisol synthesis, providing a possible explanation
for low cortisol levels in patients with meningococcal sepsis.
The observation of high ACTH levels but low cortisol and
glucose levels was highly suggestive of relative adrenal insuf-
ficiency, commonly observed in severe meningococcal sepsis
[21, 25]. Taken together with the observation of very high
circulating concentrations of MIF in nonsurvivors, the stress
hormone blood profile indicated that the immunoregulatory
balancing act played by MIF and glucocorticoids was clearly
leaning towards an overwhelming proinflammatory response
likely to contribute to multiple-organ dysfunction and death.
In summary, the present data showed that MIF was markedly
and persistently up-regulated in children and adults who had
gram-negative sepsis. High MIF levels were associated with dis-
ease severity scores, proinflammatory markers of sepsis, and
disregulated pituitary-adrenal function and early death, high-
lighting the presence of a marked imbalance between proin-
flammatory (MIF) and antiinflammatory (glucocorticoid) reg-
ulatory systems in gram-negative sepsis. Given the important
position of MIF in innate immune responses to microbial path-
ogens, these results provide a strong rationale for the devel-
opment of anti-MIF treatment strategies for the treatment of
patients with severe sepsis and septic shock.
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